Akoustis Technologies - AKTS Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTS shares.
View AKTS analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price objectives for Akoustis Technologies' shares. Their AKTS share price forecasts range from $5.00 to $9.25. On average, they expect the company's share price to reach $7.06 in the next year. This suggests a possible upside of 89.3% from the stock's current price.
View analysts price targets for AKTS or view top-rated stocks among Wall Street analysts.

Akoustis Technologies' stock was trading at $2.82 at the start of the year. Since then, AKTS shares have increased by 32.3% and is now trading at $3.73.
View the best growth stocks for 2023 here.

Akoustis Technologies, Inc. (NASDAQ:AKTS) announced its earnings results on Monday, November, 14th. The technology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.08. The technology company had revenue of $5.57 million for the quarter, compared to analysts' expectations of $5.59 million. Akoustis Technologies had a negative net margin of 342.71% and a negative trailing twelve-month return on equity of 51.16%.

Akoustis Technologies issued an update on its earnings guidance on Thursday, January, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.90 million-$5.90 million, compared to the consensus revenue estimate of $5.95 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Block (SQ), Editas Medicine (EDIT), Marvell Technology (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

Akoustis Technologies trades on the NASDAQ under the ticker symbol "AKTS."

Akoustis Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Sargent Investment Group LLC (0.90%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Arthur Geiss, David Aichele, James Michael Mcguire, Jeffrey B Shealy, Jeffrey B Shealy, Jeffrey Mcmahon, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends.

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKTS stock can currently be purchased for approximately $3.73.

Akoustis Technologies (NASDAQ:AKTS) has a market capitalization of $220.11 million and generates $15.35 million in revenue each year. The technology company earns $-59,030,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The company employs 156 workers across the globe.

Akoustis Technologies' mailing address is 9805 NORTHCROSS CENTER COURT SUITE A, HUNTERSVILLE NC, 28078. The official website for the company is www.akoustis.com. The technology company can be reached via phone at (704) 997-5735 or via email at bprag@delmarconsulting.com.